Carbinoxamine Maleate Extended-Release Oral Suspension (CARBINOXAMINE MALEATE)
Carbinoxamine Maleate Extended-Release Oral Suspension (CARBINOXAMINE MALEATE) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Carbinoxamine Maleate Extended-Release Oral Suspension; Generic name: CARBINOXAMINE MALEATE; Manufacturer: Neos Therapeutics, LP.
| Brand name | Carbinoxamine Maleate Extended-Release Oral Suspension |
|---|---|
| Generic name | CARBINOXAMINE MALEATE |
| Manufacturer | Neos Therapeutics, LP |
| Used for | 1 INDICATIONS AND USAGE Carbinoxamine Maleate extended-release oral suspension is indicated for adults and pediatric patients 2 years of age and older for the symptomatic treatment of: Seasonal and perennial allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled Amelioration of the severity of allergic reactions to blood or plasma Carbinoxamine Maleate extended-release oral suspension is an H1 receptor antagonist indi |
| Dosage | 2 DOSAGE AND ADMINISTRATION Adults and Adolescents 12 years of age and older ( 2.2 ): 7.5 mL to 20 mL (6 mg to 16 mg) orally every 12 hours Pediatric patients 2 years to 11 years of age (approximately 0.2 mg/kg/day to 0.4 mg/kg/day) ( 2.3 ): 2 years to 3 years – 3.75 mL to 5 mL (3 mg to 4 mg) orally every 12 hours 4 years to 5 years – 3.75 mL to 10 mL (3 mg to 8 mg) orally every 12 hours 6 years to 11 years – 7.5 mL to 15 mL (6 mg to 12 mg) orally every 12 hours 2.1 General Administration Instru |
| Active ingredient(s) | CARBINOXAMINE MALEATE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=199f46e5-6288-5627-e063-6294a90ae086 |